<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ICI-associated myocarditis &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ici-associated-myocarditis/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:57:41 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>ICI-associated myocarditis &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Immune Checkpoint Inhibitors Linked to Elevated Myocarditis Risk in NSCLC Patients</title>
		<link>https://bioengineer.org/immune-checkpoint-inhibitors-linked-to-elevated-myocarditis-risk-in-nsclc-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 16 May 2025 16:15:32 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ICI-associated myocarditis]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[immune-related adverse events]]></category>
		<category><![CDATA[immunotherapy cardiotoxicity]]></category>
		<category><![CDATA[NSCLC treatment risks]]></category>
		<guid isPermaLink="false">https://bioengineer.org/immune-checkpoint-inhibitors-linked-to-elevated-myocarditis-risk-in-nsclc-patients/</guid>

					<description><![CDATA[A groundbreaking editorial recently published in the latest volume of Oncoscience sheds new light on the complex relationship between immune checkpoint inhibitors (ICIs) and myocarditis, an immune-mediated inflammation of the heart muscle. As ICIs become a mainstay in the treatment of advanced non-small cell lung cancer (NSCLC), understanding their rare but serious adverse effects is [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">245542</post-id>	</item>
	</channel>
</rss>
